Ed NFkB

[Ed NFkB @edikb]

Here's a direct link to the paper published in JAMIA Open: https://t.co/N9El1PcvFx. This #openaccess article highlights how @MPishvaian and @Perthera's network of experts have made #PrecisionOncology more scalable and accessible to patients across the country through technology

[UT MD Anderson @UTMDAnderson]

“A virtual molecular tumor board allows for deep discussions and insight into many aspects of a person’s unique cancer profile,” says our @MPishvaian: https://t.co/TaoeDKmvZ7 @ASCOPost #endcancer

[Ed NFkB @edikb]

@benjiebrick I thought that the revolution will NOT be televised im so confused
https://t.co/vCNdFXBX1V

[Allison Rosenzweig @arosenzweig19]

.@YehlabUNC presenting @PanCAN Know Your Tumor data from @MPishvaian showing survival benefit of #pancreaticcancer patients receiving #precisionmedicine matched therapy. #AACRpan22

[Ed NFkB @edikb]

I'm expecting this to be a more exciting Jedi/padawan showdown than this week's obi-wan episode #pancsm #ASCO22 #medwitter @MPishvaian @marshalj23

[Cure GI Cancers @RueschCenter]

Looking forward to a great discussion on the latest in #biomarker driven treatment in #GI, #colorectal #pancreatic, and #hepatobiliary cancers with @marshalj23, @mdmanishshah, and @MPishvaian. Sign up here- https://t.co/mpYq6qZHSD to watch virtually. @CCO_Education #ASCO22

[Ed NFkB @edikb]

Great to see a shoutout to our @Perthera @PanCAN paper in @LancetOncology led by @MPishvaian at #asco22 during the Friday "Can We Begin to Predict Responders to Targeted Therapy in Gastrointestinal Cancer?" Session! https://t.co/x44YyvwhJB

[Dr Joseph McCollom DO @realbowtiedoc]

Dr Thomas Seufferlein of @UniklinikUlm shows promising data that there could be hidden subpopulations that when matched with targeted therapy may impact treatment outcomes in #pancsm #GIonc #ASCO22

[Dr Joseph McCollom DO @realbowtiedoc]

Dr Thomas Seufferlein of @UniklinikUlm shows promising data that there could be hidden subpopulations that when matched with targeted therapy may impact treatment outcomes in #pancsm #GIonc #ASCO22

[Mike Pishvaian @MPishvaian]

📢In preparation for #ASCO22, I wanted to present my list for the #PancreaticCancer abstracts to👀for @ASCO

Again,🙏note - I went through a LOT of abstracts, and I definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀

[Ed NFkB @edikb]

@SalemGIOncDoc @OncoAlert @TheLancetOncol Any biomarker contexts worth considering?

[Mike Pishvaian @MPishvaian]

It was?? That's AWESOME‼️😃🎉

🙏so much @CDebyaniPhD for 👉this

Huge CONGRATS for SUCH a TEAM🏅effort
@DrHendifar
@edikb
@Perthera
Brian Wolpin
@VivekSubbiah
Erik Collisson
Isha Singh
Tim Cannon
@kennamshaw
Chip Petricoin
@KlempnerSam
@EmilyLyons87
@WangGillam
@EileenMOReilly

[Allison Rosenzweig @arosenzweig19]

"Because the alterations are so rare, 1 single institution wouldn’t be able to draw conclusions about the best treatment approaches" @EmilyLyons87 @PanCAN - wonderful example of collaboration for the benefit of #pancreaticcancer patients! 💜

[PanCAN @PanCAN]

@ASCO_pubs Amazing collaboration w/ @DrHendifar @CSCancerCare @edikb @MPishvaian @Perthera @DanaFarber @VivekSubbiah @kennamshaw @MDAndersonNews @UCSFCancer @EileenMOReilly @sloan_kettering @GeorgeMasonU @WUSTLmed @hopkinskimmel @EmilyLyons87 @PanCAN

[PanCAN @PanCAN]

We're excited to announce a paper published today in @ASCO_Pubs #JCOPO that looks at the outcomes of #pancreaticcancer patients with alterations to the RAF gene and treatment targeted to that genetic alteration. Learn more at https://t.co/GH1inhS1Lv

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press 👉Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes. Kudos to @PanCAN team @EmilyLyons87 @arosenzweig19 @DrHendifar @MPishvaian @kennamshaw et al for the collaboration & perseverance @ASCO_pubs https://t.co/vmQihZSsyG

[Tanios Bekaii-Saab, MD @GIcancerDoc]

#PrecisionMedicine 🚨 in #pancreaticcancer

@PanCAN @lustgartenfdn @paNCfoundation

Lead @MPishvaian and Andrew Hendifar through @accru__network @MayoCancerCare

Binimetinib & Encorafenib in Pancreatic Cancer in tumors With a Somatic #BRAFV600E Mutation

https://t.co/u5Miv5fsgc

[Ed NFkB @edikb]

@drallysonocean Importantly, mutations in #BRCA and related DDR genes are NOT simply prognostic on their own (we only see a difference when platinums are used) #pancsm #PancChat https://t.co/QWoaIAbEGX

[Ed NFkB @edikb]

@Dr_R_Kurzrock A KRAS mutation rate of ~44% still isn't very high (vs >80% expected). @Perthera did this analysis 4 yrs ago and the KRAS hit rate was only ~29% (n=34), but hopefully the sensitivity of liquid biopsy tests will improve over time:
https://t.co/EJfSlCvvP9

[OncoAlert @OncoAlert]

Dear Colleagues at #ASCO20
A great pleasure to present OUR TOP #OncoAlert 🚨abstracts as picked by our expert colleague @MPishvaian
Hope they help everyone navigate the meeting in terms of #GI #Cancers #CRCSM #colorectalcancer #Cholangiocarcinoma
Best
@weoncologists

[Ed NFkB @edikb]

@s_couraud @OncoAlert What about STK11?

[Ed NFkB @edikb]

@BenWestphalen @SWOG Agreed, tough to make concrete comparisons without molecular data (BRCA/DDR at the very least). Check out @Perthera's #asco20 poster on correlations between KRAS variants and these regimens given in 1st line https://t.co/eqt2OO5qF6 #pancsm

[Ed NFkB @edikb]

@jamienholloway @gerlach_d @DavidHongMD @AACR It turns out the incidence of KRAS G12C is surprisingly rare in pancreatic cancer. Check out @Perthera's #asco20 poster on KRAS variants and their predictive/prognostic implications using real-world outcomes in #pancsm https://t.co/eqt2OO5qF6

[Ed NFkB @edikb]

@StephenVLiu Any insights into the impact of KRAS mutations on outcomes across this NSCLC population? @Perthera's #asco20 study in pancreatic cancer saw some really interesting correlations with the KRAS variants that you rarely see in NSCLC https://t.co/eqt2OO5qF6 #pancsm